World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
27988
World Ranking
16979
National Ranking
8518

David Kirn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David Kirn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 203 publications — 3rd percentile

3% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David Kirn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David Kirn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David Kirn is affiliated with the University of California, Berkeley in the United States. Their research spans multiple interconnected fields, with a primary focus on biochemistry, genetics, and molecular biology, as well as applications in medicine.

The scientist's publications cover a range of topics including virus-based gene therapy research, retinal development and disorders, CRISPR and genetic engineering, the complement system in diseases, cancer research and treatments, retinal diseases and treatments, and adenosine and purinergic signaling.

Frequent co-authors in their work include Roxanne H. Croze, Melissa Quezada, Melissa A. Kotterman, David V. Schaffer, and Peter J. Francis.

Kirn's recent research contributions include:

  • Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies, 2023, Journal of Clinical Investigation
  • Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing, 2021, Molecular Cancer Therapeutics
  • Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies, 2024, Investigative Ophthalmology & Visual Science
  • Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up, 2023, Molecular Genetics and Metabolism

Their work has been published in venues such as Molecular Genetics and Metabolism, Journal of Cystic Fibrosis, Journal of Clinical Investigation, Molecular Cancer Therapeutics, and Investigative Ophthalmology & Visual Science.

Kirn's research interests include several subfields within biology and medicine, such as molecular biology, genetics, ophthalmology, immunology, and physiology.

Best Publications

  • An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

    James R. Bischoff;David H. Kirn;Angelica Williams;Carla Heise

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

    C Heise;A Sampson-Johannes;A Williams;F McCormick

  • An essential role for Rac in Ras transformation

    Rong-Guo Qiu;Jing Chen;David Kirn;Frank McCormick

  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    Jeong Heo;Tony Reid;Leyo Ruo;Caroline J. Breitbach

  • Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

    Caroline J. Breitbach;James Burke;Derek Jonker;Derek Jonker;Joe Stephenson

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma

    J Randolph Hecht;Rudolph Bedford;James L Abbruzzese;Sandeep Lahoti

  • An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

    Carla Heise;Terry Hermiston;Leisa Johnson;Gabriel Brooks

  • Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

    Byeong Ho Park;Taeho Hwang;Taeho Hwang;Ta Chiang Liu;Daniel Y. Sze

  • Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

    Ta Chiang Liu;Evanthia Galanis;David Kirn

  • A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

    Ian Ganly;Ian Ganly;David Kirn;Susan G. Eckhardt;Gail I. Rodriguez

  • Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

    David Kirn;Robert L. Martuza;James Zwiebel

  • Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial

    John Nemunaitis;Ian Ganly;Fadlo Khuri;James Arseneau

  • Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints

    Tony Reid;Eva Galanis;James Abbruzzese;Dan Sze

  • Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

    David H. Kirn;Steve H. Thorne;Steve H. Thorne

  • Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

    D Kirn

  • Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow

    Caroline J Breitbach;Jennifer M Paterson;Chantal G Lemay;Theresa J Falls

  • Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

    S Mulvihill;R Warren;A Venook;A Adler

  • Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

    J. Nemunaitis;C. Cunningham;A. Buchanan;A. Blackburn

Frequent Co-Authors

John C. Bell
John C. Bell University of Ottawa
David V. Schaffer
David V. Schaffer University of California, Berkeley
Nicholas R. Lemoine
Nicholas R. Lemoine Queen Mary University of London
Ian Ganly
Ian Ganly Memorial Sloan Kettering Cancer Center
Frank McCormick
Frank McCormick University of California, San Francisco
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Lawrence M. Wein
Lawrence M. Wein Stanford University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
John Nemunaitis
John Nemunaitis Gradalis (United States)
Brian D. Lichty
Brian D. Lichty McMaster University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees in healthcare can open diverse pathways beyond traditional medical school. For those interested in nutrition and wellness, pursuing one of the online nutrition degrees offers flexibility and specialized knowledge for careers in dietetics, health education, or food services.

If you're aiming for leadership roles in healthcare, accredited management programs are available. Consider enrolling in one of the top online mha programs that are cahme accredited to develop essential administrative and policy-making skills.

Registered nurses looking to advance their qualifications without the need for additional clinical hours can choose from online rn to bsn programs without clinical requirements. These programs help RNs expand their expertise and improve job prospects in a convenient, online format.

Nurses aiming for the highest level of practice may be interested in doctoral options like the shortest dnp program online, providing an accelerated route to leadership, advanced clinical roles, and greater autonomy in patient care.

Best Scientists Citing David Kirn

Trending Scientists

Recently Published Articles